Early Scientific Advice At Cadth – Options and Recommendations For Future Development

Abstract

likely to delay access to rare disease and oncology therapies. Though more opaque in how assessments translated to reimbursement, interviewees noted a preference for the "added clinical benefit" VAFs in France and Germany, compared with ICERbased VAFs. ConClusions: The innovative biopharmaceutical industry recognizes relative advantages and drawbacks of established VAFs, and its assessments are supported by empiric reimbursement outcomes across therapeutic areas. Countries interested in attracting multinational pharmaceutical investment and products should understand the nuances and lessons of established systems before imposing new VAF processes.